David Chang is the founder of Allogene Therapeutics. Allogene Therapeutics has raised $420M in total funding. Latest round: IPO.
David Chang is the CEO of Allogene Therapeutics, a biotechnology company focused on developing allogeneic cell therapy products for cancer and autoimmune disorders. He led the company through its initial public offering in October 2018, which raised $372.6 million in gross proceeds, one of the largest biotechnology IPOs at that time. Under his leadership, Allogene has advanced multiple programs into clinical trials, including those targeting solid tumors and autoimmune conditions.
Full founder directory · Investor directory · Company funding database · Fundraising library